Qure advances its pathology-shifting AMT-130 therapy for Huntington's disease; pivotal data and commercial launch prep target 2025 milestones.

Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Medical-technology companies are helping revive initial public offerings in the life-sciences sector in the US after a tough ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, B.C., July 29, 2025 /PRNewswire/ -- Equity Insider News Commentary – ...

We recently published 11 Stocks That Jim Cramer Recently Talked About. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the ...

Equity Insider News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 29, 2025 /PRNewswire/ -- Equity Insider News Commentary - There's a lot of big ...

Healthcare Triangle, Inc. (NASDAQ: HCTI) recently signed major contracts with large U.S. hospital systems and expanded its AI ...

The FDA has cleared investigational new drug applications for ZW251 and RV‑01, advancing novel treatments for solid tumors in first-in-human trials.

The government identified the man as the president of Noor Inc., a supplier of merchandise to convenience stores across New England.

Baystreet.ca News Commentary – Momentum behind AI innovation is gaining traction across multiple industries, and now the U.S. government is stepping in to accelerate adoption ...

FDA officials also called for federal scheduling of the substance due to its risks, distinguishing it from the natural kratom plant.